CryoPort, Inc. (NASDAQ:CYRX) Receives $12.83 Consensus Price Target from Analysts

CryoPort, Inc. (NASDAQ:CYRX) has earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $12.8333.

A number of equities research analysts have recently commented on CYRX shares. BTIG Research raised their price target on CryoPort from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. UBS Group increased their target price on CryoPort from $11.00 to $12.50 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a report on Monday, December 29th. Finally, Needham & Company LLC lifted their price target on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th.

CryoPort Trading Up 0.6%

Shares of NASDAQ CYRX opened at $10.56 on Wednesday. CryoPort has a twelve month low of $4.58 and a twelve month high of $11.44. The stock has a market cap of $528.74 million, a price-to-earnings ratio of 9.03 and a beta of 1.54. The company has a quick ratio of 15.01, a current ratio of 15.77 and a debt-to-equity ratio of 0.40. The company’s fifty day moving average is $9.37 and its 200-day moving average is $8.93.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. The business had revenue of $44.23 million for the quarter, compared to the consensus estimate of $41.22 million. CryoPort had a negative return on equity of 11.07% and a net margin of 35.57%. Equities research analysts predict that CryoPort will post -0.99 EPS for the current year.

Insiders Place Their Bets

In related news, Director Ramkumar Mandalam sold 11,570 shares of the company’s stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $9.99, for a total value of $115,584.30. Following the completion of the transaction, the director directly owned 80,758 shares of the company’s stock, valued at approximately $806,772.42. This represents a 12.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.00% of the company’s stock.

Institutional Investors Weigh In On CryoPort

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jacobs Levy Equity Management Inc. raised its stake in CryoPort by 283.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 524,288 shares of the company’s stock valued at $4,970,000 after acquiring an additional 387,440 shares during the period. PharVision Advisers LLC boosted its position in CryoPort by 50.4% during the third quarter. PharVision Advisers LLC now owns 16,498 shares of the company’s stock worth $156,000 after purchasing an additional 5,531 shares during the period. Public Employees Retirement System of Ohio acquired a new position in shares of CryoPort in the third quarter valued at $285,000. Northwestern Mutual Wealth Management Co. raised its position in shares of CryoPort by 45.0% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 31,556 shares of the company’s stock valued at $299,000 after purchasing an additional 9,788 shares during the period. Finally, Mak Capital One LLC acquired a new stake in shares of CryoPort during the 3rd quarter worth about $7,756,000. 92.90% of the stock is owned by institutional investors.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.